Thyrotoxic Cardiomyopathy and Heart Failure in Patients with Toxic Goiter. Changes after Surgery


toxic goiter
surgical treatment
heart failure

How to Cite

Kravtsiv, V. V., Shidlovskyi, V. O., & Shidlovskyi, O. V. (2016). Thyrotoxic Cardiomyopathy and Heart Failure in Patients with Toxic Goiter. Changes after Surgery. Galician Medical Journal, 23(3).


Changes in the severity of heart failure in patients with toxic goiter after surgery are insufficiently studied.

The objective of the research was to study changes in cardiac disorders in the remote period after surgical treatment of toxic goiter.

Material and methods. The study included 48 patients with toxic goiter and moderate thyrotoxicosis and 102 patients with severe thyrotoxicosis. Cardiac disorders and changes in cardiac function after surgery were studied using the following gradation: good, satisfactory, unsatisfactory results and ineffective treatment.

Results. Good and satisfactory results of surgical treatment in patients with moderate thyrotoxicosis were obtained in 47 (98%) cases and in patients with severe thyrotoxicosis they were achieved in 45 (44%) cases. Unsatisfactory outcome was determined by the severity of thyrotoxicosis, its duration, and low exercise tolerance during the 6-min walking test.

Conclusions. Persistent severe thyrotoxicosis leads to atrial fibrillation and heart failure, which in most cases (66%) after surgical treatment of toxic goiter do not undergo reversible changes.


Babenko AYu, Grineva EN, Solntsev VN. Atrial fibrillation in thyrotoxicosis - the determinants of development and preservation. Klinicheskaya i eksperimantalnaya tireodologiya. 2013;1:29-37.

Alekseeva OA. Clinical and functional state of the cardiovascular system in patients with diffuse toxic goiter in the debut of the disease and in the remote periods after medical and surgical treatment [extended abstract of dissertation for Doctor of Medical Science]. Chelyabinsk. 2010;18.

Leynova EV, Zhilina AN. Factors contributing to the development of changes in the cardiovascular system in thyrotoxicosis, and how to correct them. Mezhdunarodnyy nauchno-issledovatelskiy zhurnal. 2013;3(11):49-51.

Leynova EV. Analysis of the effectiveness of treatment of cardiovascular complications in patients with thyrotoxicosis [extended abstract of dissertation for Doctor of Medical Science]. Volgograd. 2013;23.

Shuper VO. Clinical and pathogenetic characteristics and effectiveness of comprehensive treatment of patients with hyperthyroid heart [extended abstract of dissertation for Doctor of Medical Science]. Simferopol. 2003;20.

Flynn RWV, McDonald TM, Jung RT, et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab. 2006;91(6):2159-64.

Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005;294(1):71-80.

Osman F, Daykin J, Sheppard M, et al. Cardiac rhythm abnormalities in thyrotoxicosis - the explanation for excess vascular mortality. J Endocrinol. 2000;164:321-322.

Siu CW, Yeung CY, Lau CP, et al. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart. 2007;93(4):483-487.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.